Erythromycin is a macrolide antibiotic, which has antibacterial activity against Staphylococcus, various groups of Streptococcus and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin is only effective against bacteria that actively divide.

This product is a macrolide antibiotic. Its mechanism of action is similar to that of erythromycin, and its antibacterial spectrum is also similar to that of erythromycin, but its antibacterial activity against most Gram-positive bacteria is slightly worse. Some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin. This product also has considerable activity against diphtheria, tetani, Neisseria gonorrhoeae, pertussis, Rickettsia and Chlamydia trachomatis.

The first generation of oral cephalosporin has good antibacterial effect on most strains of penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pneumoniae, group A hemolytic Streptococcus, etc. It also has certain antibacterial activity against Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae and gonococci. Methicillin-resistant Staphylococcus, Enterococcus, indole-positive Proteus, Enterobacter, Serratia and other Enterobacteriaceae, Pseudomonas aeruginosa and Bacteroides fragilis are resistant to this product.

The first generation of oral cephalosporin has good antibacterial effect on most strains of penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pneumoniae, group A hemolytic Streptococcus, etc. It also has certain antibacterial activity against Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae and gonococci. Methicillin-resistant Staphylococcus, Enterococcus, indole-positive Proteus, Enterobacter, Serratia and other Enterobacteriaceae, Pseudomonas aeruginosa and Bacteroides fragilis are resistant to this product.

This product is a long-acting sulfonamide drug, which has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae. Its mechanism of action is that it is similar to para-aminobenzoic acid (PABA) in structure, and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from synthesizing folic acid required by bacteria as a raw material, reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymine nucleotides and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.